FLOT vs FLOT/Trastuzumab/Pertuzumab Perioperative Therapy for HER2-Positive Resectable Esophagogastric Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
J. Clin. Oncol 2022 Jun 16;[EPub Ahead of Print], RD Hofheinz, K Merx, GM Haag, C Springfeld, T Ettrich, K Borchert, A Kretzschmar, C Teschendorf, G Siegler, MP Ebert, E Goekkurt, R Mahlberg, N Homann, D Pink, W Bechstein, P Reichardt, H Flach, T Gaiser, A Battmann, FS Oduncu, M Loose, D Sookthai, C Pauligk, TO Göetze, SE Al-BatranFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.